HBM Healthcare Investments

HBM Healthcare Investments is a Swiss investment company that actively invests in emerging companies within the global healthcare sector. The firm focuses on human medicine, biotechnology, medical technology, diagnostics, therapeutics, and digital health. They maintain a well-balanced, globally diversified portfolio that includes both private and public healthcare companies, often targeting those with lead products already on the market or in advanced stages of development.

The firm was founded in July 2001 as HBM Bioventures AG by Henri B. Meier, a former Chief Financial Officer of Roche. Meier's vision was to capitalize on the trend of large pharmaceutical companies increasingly acquiring promising biotech firms rather than conducting extensive in-house research and development. HBM Healthcare Investments went public on the SIX Swiss Exchange in 2008.

HBM Healthcare Investments has made numerous notable investments across its portfolio. Key portfolio companies and investments include Terns Pharmaceuticals, which was acquired by Merck, Sharp & Dohme, as well as ALX Oncology, CORXEL Pharmaceuticals, Parabilis Medicines, Swixx BioPharma, Shanghai Cathay Biotech, Argenx, Harmony Biosciences, Zymeworks, Neurelis, ArriVent BioPharma, and Mineralys. The firm's investment strategy often involves building strategic positions by initially investing in private companies with development potential, then expanding through follow-on financing rounds and IPOs.

The company's investment activities are supported by a team with extensive expertise in both private and public healthcare investments. HBM Healthcare Investments engages HBM Partners as its investment advisor, which provides advisory services for identifying and evaluating investment opportunities, supporting portfolio companies, monitoring positions, and assessing exit strategies. The team actively guides portfolio companies on their strategic directions, leveraging a global industry network and external business advisors.